The New York Times reports that the pharmaceutical company Theranos has been working on an artificial immune system to fight infections in the body, and the drug company says it’s working on the same thing with the saliva drug.
The drug, called “Lys-Ateza” (or “Ate-za”), was first reported in The New England Journal of Medicine in October of last year.
It was originally developed by Theranos and is based on an enzyme that is part of the body’s immune system.
It’s a non-invasive way to treat infections and allergies that may be caused by viruses, bacteria, and protozoa.
“There are many examples of non-pharmacological interventions that are working on a host of diseases and disorders, including diabetes, cancer, cardiovascular disease, Alzheimer’s disease, and many others,” said Dr. David W. Levine, director of the National Institute on Aging and senior vice president of the company.
Theranos says that the new drug is “effective against HIV-1 and HIV-2, but is not as effective against influenza and tuberculosis.”
The company has been making progress in this area, but the FDA is still looking into the safety and efficacy of this new medication.
LysAteZA has been tested on people, and Theranos says it will soon begin testing on animals.
Theranos is working on testing in other animals and says it hopes to have a drug ready for clinical testing by 2019.
The company has also raised money to develop and manufacture the drug, and is looking to raise $2 billion to do so.
We’re excited to see that the drug is getting more people to the front lines and is being tested on millions of people who are not just in the U.S., but around the world.
As a part of this effort, Theranos will continue to partner with universities and research centers to study and improve the drug’s efficacy and safety.